抗体药物治疗黑色素瘤的现状及进展

Advances in antibody drugs for treatment of melanoma

摘要: 黑色素瘤的抗体药物治疗方兴未艾，其中抗CTLA-4抗体(ipilimumab和tremelimumab)及抗PD-1抗体(nivolumab 和lambrolizumab)均已完成或正在进行治疗黑色素瘤的Ⅲ期临床试验，针对其他靶点的多个抗体也处于临床试验或临床前研究阶段。本文就抗体药物治疗黑色素瘤的现状及进展做一综述，为黑色素瘤的新药开发和临床治疗提供参考。

Abstract: Antibody drugs play an important role in the treatment of melanoma. Some antibodies such as anti CTLA-4 antibodies(ipilimumab and tremelimumab)and anti PD-1 antibodies(nivolumab and lambrolizumab)have been evaluated under phase III clinical trials. This review briefly discusses recent development and advances of antibody drugs against melanoma.